Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan’s Daiichi Sankyo In “Transformational” Deal to Buy Majority Stake In India’s Ranbaxy Labs

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Japan's Daiichi Sankyo will buy a majority stake in India's top drug maker in a deal that will vault the combined operations into the top 15 pharmaceutical firms globally and end the founding Singh family's role as largest shareholder of Ranbaxy Laboratories

You may also be interested in...



Is Daiichi Sankyo Gearing Up For Arbitration Against Former Ranbaxy Owners?

Daiichi Sankyo continues to believe previous Ranbaxy shareholders concealed information related to U.S. FDA negotiations. Sources say arbitration in Singapore could be taking shape.

Let The Blame Game Begin: Former Ranbaxy Promoter Spars With Daiichi Sankyo

PharmAsia News speaks to former CEO Malvinder Singh and U.S. whistleblower Dinesh Thakur, as the stakes continue to rise in the ongoing saga of India’s Ranbaxy.

A Closer Look: Why Are Indian Pharma Promoters Diversifying Into Other Sectors?

MUMBAI - Earlier this month when Piramal Healthcare Ltd.'s Chairman Ajay Piramal announced a foray into the financial services sector, local pharma watchers were reminded of the much-touted "game-changing" deal that the scion of Ranbaxy Laboratories Ltd. Malvinder Singh struck with Daiichi Sankyo three years ago

Related Content

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel